Pimitespib (TAS-116) is a novel, potent and selective inhibitor of heat shock protein 90 (Hsp90) subtypes alpha and beta [HSP90α/HSP90β] with anticancer activity.

This product has been discontinued from InvivoChem.

KRIBB11, a novel and potent inhibitor of Heat shock factor 1 (HSF1), abolishes the heat shock-induced luciferase activity with an IC50 of 1.2 μM.

XL888 (XL-888; XL 888) is an orally bioavailable, ATP-competitive inhibitor of HSP90 (Heat Shock Protein 90) with potential antitumor activity.

BIIB021 (CNF2024; BIIB-021; CNF-2024; CNF 2024; BIIB 021) is an orally bioavailable and purine-based small-molecule inhibitor of HSP90 (heat shock protein 90) with potential anticancer activity.

SNX-2112 (SNX2112; SNX 2112; PF-04928473; PF04928473) is a novel and potent HSP90 (Heat Shock Protein 90) with potential antitumor activity and was in phase 1 clinical trials.

NVP-HSP990 (NVP HSP 990; NVP-HSP-990; HSP990; HSP-990) is an orally bioavailable HSP90 (heat shock protein 90) inhibitor with potential antitumor activity.

KNK437 (KNK-437; KNK 437; Heat Shock Protein Inhibitor I), a benzylidene lactam analog, is a novel and potent pan-HSP (heat shock proteins) inhibitor with potential antineoplastic activity.

17-DMAG (Alvespimycin, NSC-707545, BMS-826476 HCl, KOS-1022) HCl, the hydrochloride salt of 17-DMAG, is a novel and potent HSP90 (heat shock protein 90) inhibitor with potential antineoplastic activity.

CH5138303 (CH 5138303; CH-5138303) is a novel, potent, orally boavailable HSP90 (Heat Shock Protein 90) inhibitor with potential anticancer activity.